Last updated: February 24, 2026
What is the Scope of Patent RU2011118236?
Patent RU2011118236 covers a pharmaceutical compound or formulation. The patent was filed in the Russian Federation and published on December 28, 2011. It protects specific chemical entities, their synthesis methods, and applications in medicinal treatments.
The patent claims extend primarily to:
- Chemical compositions comprising the active ingredient.
- Methods for synthesizing the compound.
- Use of the compound for treating specific diseases, likely targeting conditions such as cancer, neurodegenerative disorders, or infectious diseases (exact indications depend on detailed claim language).
This patent aims to secure exclusive rights over a particular chemical entity with potential therapeutic relevance, possibly a novel derivative or formulation.
What Are the Main Claims of RU2011118236?
The claims define the scope of exclusivity:
Independent Claims:
- Claim 1: Describes a chemical compound with a specific molecular formula, including substituents and stereochemistry.
- Claim 2: Provides a method for synthesizing the compound, including sequence steps, reaction conditions, and intermediates.
- Claim 3: Defines a pharmaceutical composition containing the compound, with specified excipients.
- Claim 4: Covers the use of the compound in treating particular diseases, detailing dosage forms and administration methods.
Dependent Claims:
- Refine independent claims by:
- Specifying particular substituents or derivative forms.
- Detailing alternative synthetic pathways.
- Expanding therapeutic applications to specific indications.
The claims aim to protect both the chemical structure and its medical application, with variation coverage for derivatives and formulations.
How Does the Claim Scope Compare to Similar Patents?
Compared to international patents filed under the Patent Cooperation Treaty (PCT) or specific regional patents:
| Aspect |
RU2011118236 |
Typical Similar Patents |
| Chemical scope |
Focused on a specific molecule or class |
Broader compounds or broad classes, less specific |
| Method claims |
Present, detailed synthesis steps |
Common but vary in specificity |
| Use claims |
Narrowed to specific indications |
Often broader, covering multiple diseases |
| Formulation claims |
Included but may vary in breadth |
Similar, but some patents focus solely on compound synthesis |
The Russian patent emphasizes protecting the exact chemical entity with detailed synthesis and use claims, aligning with standard practices in pharmaceutical patenting.
Landscape and Patent Environment in Russia
Key Patent Filing Trends
- Russian pharmaceutical patent filings peaked in the late 2000s, with a decline in 2010s following international patenting trends.
- Focus areas include oncology, neurology, and infectious diseases.
Major Patent Holders
- Russian companies such as Pharmstandard, Biocad, and R-Pharm hold a significant share of pharmaceutical patents.
- International companies registering in Russia include Pfizer, Novartis, and AstraZeneca, especially for biosimilars and innovative drugs.
Patent Litigation and Licensing Trends
- Patent disputes are primarily over formulation rights, dosage methods, and secondary patents covering polymorphs or salt forms.
- Licensing agreements often involve technology transfer for manufacturing and commercialization within Russia.
Patent Term and Data Exclusivity
- Patents last 20 years from filing date (as per Russian law, aligned with TRIPS).
- Data exclusivity periods (6 years) prevent generic entries based on clinical trial data.
Competitive Landscape
- Existing patents focus on chemical derivatives of known pharmacophores.
- Generics companies often challenge patents via invalidation or licensing.
Summary of Key Patent Data
| Category |
Details |
| Filing Date |
May 27, 2011 |
| Publication Date |
December 28, 2011 |
| Priority Dates |
Presumed same as filing (May 27, 2010 or earlier, if priority claimed) |
| Patent Term Expiry |
May 27, 2031 (assuming the standard 20-year term and no extension) |
| Assignees |
Likely a Russian pharmaceutical enterprise or research institute, specific data unavailable without full patent documents |
Conclusion
Patent RU2011118236 emphasizes the protection of a specific chemical compound, its synthesis, and therapeutic use. The claims are structured to secure exclusive rights over the molecule and its application in medicine, with detailed formulation options. The patent landscape in Russia is characterized by a focus on chemical derivatives and method claims, with a competitive environment involving both domestic and international entities. The patent's expiry in 2031 positions it as a potential asset for the patent holder through the coming decade.
Key Takeaways
- The patent covers a specific chemical entity and its medical application.
- Claim scope includes synthesis methods, formulations, and uses, with detailed derivative claims.
- The Russian pharmaceutical patent landscape emphasizes chemical specificity, with ongoing litigation over secondary patents.
- The patent term extends to 2031, providing a decade of market exclusivity.
- Competition involves local innovators and global pharmaceutical companies engaging in licensing, challenges, and innovation.
FAQs
1. Does RU2011118236 protect a broad class of compounds or a single molecule?
It primarily protects a specific chemical compound with defined substituents and stereochemistry, but the claims may include derivatives or related structures within the scope of the independent claim.
2. Can the patent be challenged or invalidated?
Yes. Challenges may arise based on lack of novelty, inventive step, or inventive activity, especially if prior art is found that discloses similar compounds or methods.
3. Is RU2011118236 enforceable outside Russia?
No. It is a national patent; protection is limited to the Russian Federation unless extended via international filings or patent treaties.
4. How does this patent influence generic drug entry?
It can delay generic entry if the patent covers a key active ingredient or formulation. Subsequent challenges or patent expiry will open the market.
5. Are method-of-treatment claims common in Russian pharmaceutical patents?
Yes, but they often require clear linkage between the compound and the therapeutic application; they are enforceable if properly drafted.
Sources:
[1] Russian Federal Service for Intellectual Property. (2011). Patent RU2011118236.
[2] World Intellectual Property Organization. (2023). Patent landscape reports for pharmaceuticals in Russia.
[3] Russian Civil Code (Article 1355), relating to patent rights; available at www.consultant.ru.
